How does Abbott Laboratories (ABT) make money?

Abbott Laboratories (ABT) generates revenue primarily from Medical Devices, which accounted for 40.7% of total revenue in TTM through Q1 2026. The company reported $45.13B in revenue and converted 13.9% of it into net profit, equivalent to roughly $6.28B in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of Abbott Laboratories (ABT)?

Abbott Laboratories (ABT) reported a gross profit margin of 56.4% in TTM through Q1 2026, equivalent to $25.45B in gross profit on $45.13B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of Abbott Laboratories (ABT)?

Abbott Laboratories (ABT) reported an operating profit margin of 18.2% in TTM through Q1 2026, equivalent to $8.20B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of Abbott Laboratories (ABT)?

Abbott Laboratories (ABT) reported a net profit margin of 13.9% in TTM through Q1 2026, equivalent to $6.28B in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is Abbott Laboratories (ABT) profitable?

Yes. Abbott Laboratories (ABT) reported $6.28B in net income for TTM through Q1 2026, with a net profit margin of 13.9%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does Abbott Laboratories (ABT) invest in research and development?

Abbott Laboratories (ABT) invested $3.01B in research and development during TTM through Q1 2026, roughly 6.7% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does Abbott Laboratories (ABT) spend on capital expenditures?

Abbott Laboratories (ABT) spent $2.09B on capital expenditures (CapEx) during TTM through Q1 2026, roughly 4.6% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does Abbott Laboratories (ABT) generate?

Abbott Laboratories (ABT) generated $7.38B in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 16.3%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of Abbott Laboratories (ABT)?

Abbott Laboratories (ABT) had an effective tax rate of 22.9% in TTM through Q1 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of Abbott Laboratories (ABT)?

Abbott Laboratories (ABT) reports revenue across 4 reportable product segments, led by Medical Devices at 40.7% of total revenue in TTM through Q1 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

Where does Abbott Laboratories (ABT) generate most of its revenue?

Non-US is the largest geographic market for Abbott Laboratories (ABT), accounting for 54.7% of revenue in the most recent annual filing. The complete regional split — including international markets and any Rest-of-World rollup — is shown in the revenue-by-geography table on this page.

How Abbott Laboratories Makes Money: 2026 Visual Revenue Map

Abbott Laboratories (ABT) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported April 29, 2026).

Abbott Laboratories (ABT) Revenue by Product Segment — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for Abbott Laboratories (ABT) in TTM through Q1 2026.
Segment	Revenue (USD)	% of total
Medical Devices	$18.36B	40.7%
Diagnostic Products	$15.08B	33.4%
Nutritional Products	$6.94B	15.4%
Established Pharma	$4.75B	10.5%
Total	$45.13B	100%

Medical Devices$18.36B
Diagnostic Products$15.08B
Nutritional Products$6.94B
Established Pharma$4.75B
Total$45.13B

Abbott Laboratories (ABT) Revenue by Geography — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.

Revenue contribution by geographic region for Abbott Laboratories (ABT), TTM through Q1 2026
Region	Revenue (USD)	% of total
Non-US	$20.83B	54.7%
UNITED STATES	$17.23B	45.3%
Total	$38.06B	100%

Non-US
UNITED STATES
Total

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, Abbott Laboratories (ABT) reports revenue across 4 operating segments; the largest segment was Medical Devices at 40.7%, followed by Diagnostic Products (33.4%) and Nutritional Products (15.4%). Separately, by end-market geography, Non-US accounted for 54.7% of revenue, followed by UNITED STATES (45.3%).

Frequently asked questions

Data & methodology

Abbott Laboratories (ABT) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation